# FDA Approves Vepdegestrant (Veppanu), First-Ever PROTAC Cancer Drug, for ER+ Metastatic Breast Cancer

> fda · REPORTED · 2026-06-30

The FDA approved vepdegestrant (Veppanu) as the first-ever proteolysis-targeting chimera (PROTAC) to receive FDA approval for any cancer, clearing it for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed after at least one prior line of endocrine therapy in Q2 2026. This marks a historic milestone as a first-in-class ER degradation mechanism distinct from SERDs.

About Arvinas / FDA: Arvinas is a biopharmaceutical company pioneering PROTAC protein degrader technology to develop targeted therapies for cancer and other serious diseases.

- Company: Arvinas / FDA
- Sector: oncology
- Primary source: https://www.aacr.org/blog/2026/07/02/fda-approvals-in-oncology-april-june-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.